🫁 Biologic Therapy for Severe Eosinophilic Asthma Simulator

Severe Eosinophilic Asthma — The Type 2 Inflammatory Cascade

IgE and IL-5 drive eosinophils to damage the airway wall.

• 650/µL: Blood eosinophils (well above the 300 threshold)
• 450 IU/mL: Serum IgE (markedly elevated allergic antibody)
• 4.2: Annual exacerbations (flare-ups needing oral steroids)
• 15 mg: Oral steroid dose (daily prednisone maintenance dose)

IgE sensitizes mast cells

Allergen-specific IgE coats mast cells through FcεRI receptors.

IL-5 sustains eosinophils

IL-5 drives eosinophil maturation, survival, and tissue recruitment.

Severe eosinophilic asthma affects roughly five percent of asthma patients.

Th2 cytokines remodel airways

IL-4 and IL-13 thicken mucus and tighten smooth muscle.

Omalizumab — Neutralizing Free IgE Before It Binds

Omalizumab intercepts circulating IgE, disarming mast cells early.

• Free IgE: Target (circulating allergic antibody)
• Anti-IgE mAb: Mechanism (humanized monoclonal antibody)
• 2–4 wk: Dosing interval (subcutaneous injection schedule)
• 2003: Approved since (first approved asthma biologic)

Binds free IgE

Omalizumab forms small complexes with circulating IgE molecules.

Blocks FcεRI engagement

Bound IgE can no longer dock onto mast cell receptors.

Omalizumab works best in patients with a confirmed allergic trigger.

Calms the allergic cascade

Mast cell degranulation and histamine release drop sharply.

Mepolizumab — Cutting Off the Eosinophil Survival Signal

Mepolizumab blocks IL-5, starving eosinophils in the bone marrow.

• IL-5 cytokine: Target (eosinophil growth factor)
• Anti-IL-5 mAb: Mechanism (humanized monoclonal antibody)
• ~90%: Eosinophil reduction (typical blood count drop)
• 2015: Approved since (first-in-class Nucala approval)

Neutralizes circulating IL-5

Mepolizumab binds IL-5 before it reaches its receptor.

Starves eosinophil production

Bone marrow eosinophil maturation and release slow dramatically.

Mepolizumab cuts severe exacerbation rates by roughly half in trials.

Shortens eosinophil lifespan

Circulating eosinophils undergo apoptosis without survival signaling.

Dupilumab — Silencing the Shared Th2 Receptor

Dupilumab blocks IL-4Rα, muting both IL-4 and IL-13 signals.

• IL-4Rα subunit: Target (shared cytokine receptor chain)
• Anti-IL-4Rα mAb: Mechanism (blocks two cytokines at once)
• ~65%: Exacerbation reduction (in severe asthma trials)
• 2018: Approved since (Dupixent asthma indication added)

Blocks the shared receptor

One antibody stops both IL-4 and IL-13 signaling.

Reduces mucus and remodeling

Goblet cell mucus production and airway thickening decline.

Dupilumab often enables the steepest oral steroid taper of the three.

Broadens Th2 suppression

Eosinophil recruitment and IgE class-switching both fall.

Clinical Remission — Sustained Control on Biologic Therapy

Eosinophils, exacerbations, and steroid dose all stay low.

• <150/µL: Blood eosinophils (sustained on treatment)
• <1/yr: Exacerbations (down from over four)
• <5 mg: Oral steroid dose (often discontinued entirely)
• Improved FEV1: Lung function (fewer symptomatic days overall)

Steroid-sparing effect

Biologics let most patients taper off oral steroids.

Durable eosinophil suppression

Blood and airway eosinophils stay low with continued dosing.

Stopping a biologic often lets inflammation and symptoms return.

Fewer exacerbations, better quality of life

Hospitalizations and daily symptom burden drop substantially.